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BACKGROUND. Our goal was to investigate de novo purine biosynthetic gene PAICS
expression and evaluate its role in prostate cancer progression.
METHODS. Next-generation sequencing, qRTPCR and immunoblot analysis revealed an
elevated expression of a de novo purine biosynthetic gene, Phosphoribosylaminoimidazole
Carboxylase, Phosphoribosylaminoimidazole Succinocarboxamide Synthetase (PAICS) in a
progressive manner in prostate cancer. Functional analyses were performed using prostate
cancer cell lines- DU145, PC3, LnCaP, and VCaP. The oncogenic properties of PAICS were
studied both by transient and stable knockdown strategies, in vivo chicken chorioallantoic
membrane (CAM) and murine xenograft models. Effect of BET bromodomain inhibitor JQ1
on the expression level of PAICS was also studied.
RESULTS. Molecular staging of prostate cancer is important factor in effective diagnosis,
prognosis and therapy. In this study, we identified a de novo purine biosynthetic gene; PAICS
is overexpressed in PCa and its expression correlated with disease aggressiveness. Through
several in vitro and in vivo functional studies, we show that PAICS is necessary for
proliferation and invasion in prostate cancer cells. We identified JQ1, a BET bromodomain
inhibitor previously implicated in regulating MYC expression and demonstrated role in
prostate cancer, abrogates PAICS expression in several prostate cancer cells. Furthermore, we
observe loss ofMYC occupancy on PAICS promoter in presence of JQ1.
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CONCLUSIONS. Here, we report that evaluation of PAICS in prostate cancer progression
and its role in prostate cancer cell proliferation and invasion and suggest it as a valid
therapeutic target. We suggest JQ1, a BET-domain inhibitor, as possible therapeutic option
in targeting PAICS in prostate cancer. Prostate 77:10–21, 2017. # 2016 Wiley Periodicals, Inc.
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INTRODUCTION
Prostate cancer (PCa) is one of the most
common cancers among men in the United States
and across the world [1,2]. Prostate organ func-
tion is critically dependent on steroid hormone
androgen. Early stages of localized prostate can-
cer are usually androgen receptor (AR) dependent
and therefore can be effectively treated with anti-
androgens. However, over time PCa progresses
into a castration resistant prostate cancer (CRPC)
that can be either androgen dependent or inde-
pendent. The CRPCs are genetically and molecu-
larly heterogeneous, aggressive, and metastatic
PCa are lethal [3].
Besides AR, aberrant levels of MYC expression
either as genetic dysregulation (amplification) or
epigenetic modulation (increased expression) in
PCa is associated with poor prognostication [4–6].
However, MYC is a transcription factor that regu-
lates myriad of metabolic pathways which includes
but is not limited to purine biosynthesis, amino
acid metabolism, glycolysis, etc. [7,8]. MYC target-
ing has been difficult endeavor and is considered
“undruggable” [9]. Alternate strategies to counter
MYC-mediated oncogenesis include targeting syn-
thetic lethal partners for MYC or pathways
regulated directly or indirectly by increased MYC
expression [10]. MYC mediated regulation of purine
biosynthetic pathway have recently been demon-
strated in androgen sensitive prostate cancer
cells [8].
Recently, there has been renewed appreciation of
role of metabolism in cancer initiation, progression,
and metastasis [11]. Numerous metabolic genes and
metabolites have become candidates for diagnosis,
prognosis, and therapeutic targeting. For example,
IDH1 and IDH2 mutations have been discovered to
confer altered properties that results in production of
a-hydroxyglutarate instead of a-ketoglutarate [12].
This in turn triggers epigenetic changes that promote
oncogenesis. Sarcosine accumulation during prostate
cancer progression is potential diagnostic marker [13].
Among other examples, amino acids such as glycine
and glutamine dependency of rapidly proliferating
cells, cancer specific activation of isoform variants of
hexokinase (hexokinase2) have therapeutic potential
[14].
Our present study discovered an increased ex-
pression of de novo purine metabolic enzyme
Phosphoribosylaminoimidazole Carboxylase, Phos-
phoribosylaminoimidazole Succino carboxamide
Synthetase, (PAICS) in prostate cancer. Our analyses
show increased PAICS expression, which correlates
with progression of prostate cancer from benign,
localized to metastatic cancer thereby revealing its
potential as a progression marker. Through in vitro
and in vivo studies, we demonstrate the necessary
role of PAICS in prostate cancer cell growth,
invasion, and metastasis. We demonstrate that
PAICS expression can be abrogated using JQ1, a
BET-domain protein inhibitor, potentially through
direct targeting of MYC protein. Our study reveals
PAICS as a marker of disease progression. In
addition, we show its essential role in tumor
growth and metastasis that can be potentially




Prostate cancer cell lines DU145, PC3, and LnCaP
were grown in RPMI 1640 (Life Technologies, NY),
while VCaP was grown in DMEM with penicillin-
streptomycin (100U/ml) and 10% FBS (Invitrogen) in
5% CO2 cell culture incubator. Prostate cancer cells
were infected with lentiviruses expressing PAICS
shRNA or non-targeting shRNA controls and stable
cell lines were generated by selection with 1mg/ml
puromycin (Life Technologies).
Benign and Tumor Tissues
In this study, we utilized tissues from clinically
localized prostate cancer patients who underwent
radical prostatectomy. Samples were also obtained
from androgen-independent metastatic prostate can-
cer patients from a rapid autopsy program through
the University of Michigan Prostate SPORE Tissue
Core as described previously [15,16]. The detailed
clinical and pathological data are maintained in a
secure relational database. The Institutional Review
Board at the University of Michigan Medical School
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approved this study. Both radical prostatectomy
series and the rapid autopsy program are part of
the University of Michigan Prostate SPORE Tissue
Core.
Gene Expression From The Cancer Genome
Atlas (TCGA)
The patients clinical data for prostate adenocarci-
noma (PRAD) were downloaded using TCGA-assem-
bler [17]. However, downloaded data comprised of
only tumor pathologic (pT) and node pathologic (pN)
information. Thus based on pT and pN data as per
“https://cancerstaging.org/references-tools/quic
kreferences/Documents/ProstateSmall.pdf,” samples
were categorized into primary and metastatic tumor.
Afterwards, level3 TCGA RNA-seq data (including
raw_read_count and scaled_estimate for each sample)
for all primary tumor, metastatic tumor, and matched
normal samples were downloaded using TCGA-as-
sembler. Transcript per million values for each gene
was obtained by multiplying scaled_estimate by
1,000,000. Boxplot was generated using R [https://
cran.r-project.org/].
Immunohistochemistry
Benign and prostate cancer tissues were
obtained from the radical prostatectomy series at
the University of Michigan and from the Rapid
Autopsy Program, both part of the University of
Michigan Prostate SPORE programs, through ap-
propriate informed consent. Institutional Review
Board approval was obtained to procure and
analyze the tissues used in this study. Immunohis-
tochemistry (IHC) was carried out to evaluate
PAICS expression using mouse monoclonal anti-
body against PAICS (GeneTex, CA, Cat#
GTX83950). IHC was performed using an auto-
mated protocol developed for the DISCOVERY XT
automated slide staining system (Ventana Medical
Systems, Inc.,) using Ultramap anti-mouse HRP
(Cat# 760-4313,Ventana Medical Systems, Inc.,) and
was detected using ChromoMap DAB (Cat#760-
159, Ventana Medical Systems Inc.). Hematoxylin II
(Cat#790-2208 Ventana-Roche, Tucson, AZ) was
used as the counterstain. The study pathologist Dr.
Kunju (P.K.) evaluated IHC staining.
PAICS Progression Analysis (TMA 145)
TMA 145 contained 213 cores from 57 patients.
After exclusion of lost, stromal, and necrotic
tumor cores, 167 cores remained from 50 patients.
After exclusion of HGPIN samples, 156 cores
remained from 49 patients. Cores were only
retained for subsequent analysis if their intended
status (localized cancer vs. benign) agreed with
the evaluation status, resulting in 149 cores from
49 patients. Product score (the product of staining
percentage, 0–100%, and staining intensity, 0–4),
was computed for each core, resulting in a
measurement of staining ranging from 0 to 400.
Multiple cores from the same patient were aggre-
gated whenever they were of the same type
(benign, localized cancer, or metastatic) by taking
the median product score across cores for that
patient. This resulted in 54 data points from 49
patients. The five patients with multiple measure-
ments each contained both cancer and benign
cores on the TMA.
Immunoblot Analyses
Antibodies used in the study are listed in Table
SI. All antibodies were employed at dilutions
optimized in our laboratory. For immunoblot anal-
ysis, 10mg protein samples were separated on a
SDS–PAGE and transferred onto Immobilon1-P
PVDF membrane (EMD Millipore, Billerica, MA).
The membrane was incubated for 1 hr in blocking
buffer (Tris-buffered saline, 0.1% Tween [TBS-T],
5% nonfat dry milk) followed by incubation over-
night at 4°C with the primary antibody. After two
washes for 5min each with TBS-T, the blot was
incubated with horseradish peroxidase-conjugated
secondary antibody (1:5000) for 1 hr at room
temperature and signals were visualized by Lumi-
nataTM Crescendo chemiluminescence western
blotting substrate as per manufacturer ’s protocol
(EMD Millipore).
RNA Interference and Transfection
The PAICS and non-targeting small interfering
RNA (siRNA) duplexes (Table SII) were purchased
from Dharmacon, Lafayette, CO (GE Healthcare).
Transfections were performed with Lipofectamine1
RNAiMAX (Life Technologies) reagent. PAICS
shRNAs (Table SII) were purchased from SBI
(System Biosciences, Mountain View, CA). Lenti-
viruses for these stable knockdowns were generated
by the University of Michigan Vector Core. For
RNA interference, we seeded prostate cancer cells
at 1105 cells per well in a 6-well plate and 12 hr
later the cells were transfected with siRNA
duplexes. A second identical transfection was per-
formed 24 hr later. Seventy-two hours after the first
transfection, cells were harvested for RNA isolation
or immunoblot analysis.
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Treatment With JQ1
Prostate cancer cells—DU145, PC3, LnCaP,and
VCaP cells were seeded in 6-well plates and propa-
gated at 37°C in an atmosphere of 5% CO2 in a
humidified incubator overnight. Cells were then
treated with 1 or 5mM of JQ1 (Cat# 27400; BPS
Bioscience, Inc., San Diego, CA). JQ1 was dissolved in
dimethyl sulfoxide (DMSO; Thermo Fisher Scientific,
Waltham, MA).
Cell Proliferation Assays
Cell proliferation was measured by cell counting.
For this, transient and stable PAICS knockdowns
were used. After 72 hr of transfection using specific
siRNA, the cells were trypsinized and seeded at a
density of 10,000 cells/well in 24-well plates (n¼ 3).
Non-targeting si/sh-RNA-treated cells were served
as controls. Then the cells were trypsinized and
counted at specified time points by Z2 Coulter
particle counter (Beckman Coulter, Brea, CA). Each
experiment has been performed with three repli-
cates per sample.
Cell Cycle Analyses
PC3 cells transfected with non-targeting siRNAs
or PAICS siRNAs in 6-well plate were (1105 cells/
well) resuspended in 0.5ml Dulbecco’s phosphate-
buffered saline (DPBS). Drop-wise 100% cold etha-
nol was added to the cells. The cells were vortexed
and incubated in Ethanol for 20min, before storing
at 4°C for further use. For staining, cells in alcohol
were pelleted (2000 rpm/5min). The alcohol was
decanted and cells were washed with DPBS twice.
Then, the cells were resuspended in DPBS contain-
ing 50mg/ml propidium iodide and 100mg/ml
RNase A. Cells were incubated in dark for 20min
before flow cytometry analyses. Each sample was
measured in triplicate.
Wound Healing Assay
Prostate cancer cells—DU145, PC3 scramble
shRNA, or PAICS stable knock down cells were
seeded in 6-well plates in RPMI-1640 containing
10% fetal bovine serum and puromycin (1mg/ml),
and then allowed to grow to confluent monolayer.
The cells were serum starved for 12 hr and replen-
ished with 10% FBS-RPMI medium. The wound-
induced migration was triggered by scraping the
cells with a 200ml pipette tip, washed with D-PBS
and replenished with respective medium. The
wound was imaged immediately (0 hr) and at 12 hr
with an inverted phase-contrast microscope under
4 objective.
Matrigel Invasion Assay
Matrigel invasion assays were performed as
described earlier [18–20]. Various test cells were
seeded onto Corning1 BioCoatTM matrigel1 matrix
(Corning, New York) in the upper chamber of a 24-
well culture plate. The lower chamber containing
respective medium was supplemented with 10%
serum as a chemo-attractant. After 48 hr, the non-
invading cells and matrigel matrix were gently
removed with a cotton swab. Invasive cells located
on the lower side of the chamber were stained with
0.2% crystal violet in methanol, air-dried, and
photographed using an inverted microscope (4).
The invaded cells were quantified by colorimetric
assay. For colorimetric assays, the inserts were
treated with 150ml of 10% acetic acid and the
absorbance measured at 560 nm.
Colony Formation Assay
After 72 hr of transfection, untreated, non-target-
ing, and PAICS siRNA treated cells were counted
and seeded 800 cells per one well of 6-well plates
(triplicates) and incubated at 37°C, 5% CO2 for 10
days. Colonies were fixed with 10% (v/v) glutaral-
dehyde for 30min and stained with crystal violet
(St. Louis, MO) for 20min. Then the photographs
of the colonies were taken using Amersham Im-
ager 600RGB (GE Healthcare Life Sciences, PA).
Colony quantification was done using ImageQuant
TL Colony v8.1 software (GE Healthcare Life
Sciences).
Chromatin Immunoprecipitation (ChIP) Assays
ChIP assays were carried out with respective
antibodies (Table SI) using the EZ-Magna ChIP kit
(Millipore) as described [19]. The primer sequen-
ces for the promoters analyzed are provided in
Table SIV.
Chicken Chorioallantoic Membrane (CAM) Assay
The CAM assay for local cell invasion, intravasa-
tion, metastasis, and tumor (or xenograft) formation
was performed as previously described [18–22]. After
3 days of implanting the cells in each egg, lower CAM
was harvested and extra-embryonic tumors were
isolated and weighed. For metastasis assay, the
embryonic livers were harvested on day 18 of embry-
onic growth and analyzed for the presence of tumor
Purine Biosynthetic Gene in Prostate Cancer 13
The Prostate
cells by quantitative human Alu-specific PCR. Geno-
mic DNA from lower CAM and livers were prepared
using Puregene DNA purification system (Qiagen,
Valencia, CA) and quantification of human-Alu was
performed as described [18–22]. An average of eight
eggs per group was used in each experiment.
Tumor Xenograft Model
All procedures involving mice were approved by
the University Committee on Use and Care of
Animals (UCUCA) at the University of Michigan
and conform to all regulatory standards. To evalu-
ate the role of PAICS in tumor formation in vivo,
we propagated stable PAICS knockdown PC3 cells
using two-independent shRNAs and non-targeting
shRNA control cells, and inoculated 1106 cells
subcutaneously into the dorsal flank of 5-week-old
male Athymic nude mice (n¼ 8 for each group;
Harlan Laboratories, Evigo Indianapolis, IN). The
tumor data obtained using scramble cells is same as
used in an earlier study since PAICS tumor xeno-
graft study was conducted simultaneously using
common control animals [19]. Tumor size was
measured biweekly, and tumor volumes were calcu-
lated using the formula (p/6) (LW2), where L¼
length and W¼width of the tumor. After end of
the experiment, mice from different groups were
sacrificed; the tumors were then photographed,
weighed, and plotted.
Statistical Analysis
To determine significant differences between two
groups, Student’s two-tail t-test was used for all
experiments except for microarray, P values <0.05
considered significant.
RESULTS
Through the analysis of publicly available pros-
tate cancer gene expression profiling data, tran-
scriptome sequencing data we establish
overexpression of de novo purine biosynthetic
enzyme PAICS in prostate cancer. Furthermore,
immunohistochemistry with prostate tissue micro-
array demonstrate PAICS expression increases with
disease progression with metastatic prostate cancer
having highest expression. Through RNA interfer-
ence studies we show that PAICS is necessary for
prostate cancer cell growth, invasion, and colony
formation suggesting PAICS is required for cancer
cells. We then demonstrate that PAICS is necessary
for tumor growth and metastasis by xenograft
studies in mouse and chorioallantoic membrane
assay (CAM). Finally, we demonstrate that PAICS
expression can be targeted using JQ1, an inhibitor
of BET bromodomain proteins possibly through
disruption of MYC-mediated PAICS regulation. We
therefore conclude that PAICS is potential bio-
marker for prostate cancer and amenable to thera-
peutic targeting using BET-domain inhibitors.
PAICS Is a Biomarker for Prostate Cancer
Progression
Our analysis of publicly available prostate cancer
gene expression profiling data using Oncomine
database [OncomineTM Platform] (Life Technologies,
Ann Arbor, MI) [23] suggested significant over-
expression of PAICS in multiple independent gene
expression profiling studies (Fig. 1A). Analysis of
transcriptome sequencing data of prostate cancer
confirmed the increased PAICS expression in pri-
mary prostate cancer as well as metastatic prostate
tumors (Fig. 1B). Moreover, TCGA data shows that
PAICS is over-expressed in metastatic prostate ade-
nocarcinoma (Fig. 1C). Next, we validated this
observation by immunoblot analysis using specific
antibody against PAICS, which showed a signifi-
cantly increased PAICS protein in primary and
metastatic PCa tissue lysates (Fig. 1D). Furthermore,
we validated our observations through immunohis-
tochemistry using a prostate tissue microarray con-
taining multiple benign, primary PCa, and
metastatic PCa samples (Fig. 1E). We observed a
strong cytoplasmic staining for PAICS in primary
PCa as well as metastatic PCa. The staining inten-
sity analysis indicated that PAICS is a progression
associated marker with increasing expression ob-
served from primary PCa and Metastatic PCa (Fig.
1F). The difference in PAICS product scores be-
tween benign and localized cancer patients is
statistically significant (P< 0.001, Student’s t-test),
as is the difference between benign and metastatic
tissues (P< 0.001).
PAICS Is Essential for Prostate Cancer Cell
Proliferation and Invasion
To determine the role of PAICS in prostate cancer
cell growth, we transiently knocked down PAICS
using two specific and independent siRNA duplexes
in aggressive prostate cancer cell lines DU145 and
PC3 and conducted cell proliferation, invasion, and
colony formation experiments. Knockdown of PAICS
was observed by immunoblot analysis (Fig. 2A).
Simultaneously, the cell proliferation assays were
conducted in DU145 and PC3 cells by counting the
cells at various time intervals. PAICS knockdown
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reduced prostate cancer cell proliferation (Fig. 2B).
PAICS knockdown reduced the number of colonies as
compared to untreated and non-targeting siRNA
treated cells as measured by colony formation assay
(Fig. 2C). Furthermore, knockdown of PAICS reduced
cancer cell invasion as measured by Boyden chamber
matrigel invasion assay (Fig. 2D). Additionally, stable
knockdowns of PAICS were achieved using two
specific and independent shRNAs both in DU145 and
PC3 cells (Supplementary Fig. S1A). Similar to tran-
sient knockdowns, stable knockdowns also reduced
prostate cancer cell proliferation (Supplementary Fig.
S1A). Moreover, knockdown cells displayed reduced
cell motility as compared to non-targeting shRNA
cells (Supplementary Fig. S1B). Cell cycle analysis in
PAICS knockdown, showed decreased population in
Fig. 1. De novo purine biosynthetic enzyme PAICS shows increased expression in prostate cancer. (A) Gene expression profiling
analysis of multiple prostate cancer datasets using Oncomine database suggest PAICS expression across the datasets [24–33] between
normal prostate and primary prostate cancer (The rank for a gene is the median rank for that gene across each of the analyses. The
P-value for a gene is its P-value for the median-ranked analysis.). (B) Transcriptome sequencing of prostate cancer. PAICS expression
in benign, primary, and metastatic prostate cancer were measured in RPKM (read per million Kilobase). (C) Expression of PAICS in
normal prostate, primary, and metastatic tumor samples from TCGA. (D) Immunoblot analysis of PAICS using lysates from benign
prostate, primary prostate, and metastatic prostate cancer tissue lysates. b-actin served as a loading control. (E) Immunohistochemi-
cal (IHC) staining of prostate tissue with PAICS specific antibody. (F) IHC staining was scored and the intensity was measured as
product score and plotted as box plots.
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G1 and increased S-phase arrested cells consistent
with PAICS role in purine biosynthesis (Supplemen-
tary Fig. S2). Thus, these in vitro experiments demon-
strated the essential role of PAICS in prostate cancer
cell proliferation, colony formation, and invasion.
Role of PAICS in Prostate Cancer Tumor
Growth
To substantiate the in vitro experiments, we took
advantage of both in vivo CAM (chick chorioallan-
toic membrane) assay and mouse xenograft models.
Earlier, CAM assays were used successfully as an in
vivo model to investigate the tumorigenic potential,
to assess cell intravasation and metastasis to distant
organs [19–22]. To test this, we generated two
independent stable PAICS knockdowns in prostate
cancer cells (Fig. 3A). These stable PAICS knock-
down cells showed a significant reduction in tumor
weight (Fig. 3B), as well as decreased intravasation
(Fig. 3C) and metastasis (Fig. 3D) to liver. We
demonstrate that PAICS knockdown impairs ability
of prostate cells to grow, invade, and metastasize.
Independently, we used mouse prostate xenograft
model for tumor growth using athymic nude mice
to check role of PAICS in tumor growth and
progression. As observed in CAM assay, we saw
significant reduction in tumor growth and weight
of PAICS shRNA cells compared to control shRNA
cells (Fig. 3E and F), demonstrating its in vivo
crucial role in prostate tumor growth.
Bromodomain Inhibitor JQ1 Inhibits PAICS
Expression
Inhibitors of bromodomain and extra-terminal
(BET) domain family of epigenetic reader proteins
have been demonstrated in anti-tumor activity in
Fig. 2. Purine biosynthetic pathway enzyme PAICS is required for prostate cancer cell proliferation and invasion. (A) Immunoblot
analysis of PAICS using lysates from aggressive prostate cancer cell lines DU145 and PC3 treated with two specific and independent PAICS
siRNA duplexes or non-targeting siRNA. b-actin served as a loading control. (B) Knockdown of PAICS reduced the prostate cancer cell
proliferation and (C) colony formation and (D) invasion in Boyden chamber matrigel invasion assay, respectively.
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Fig. 3. PAICS plays a role in prostate cancer growth and metastasis in vivo. (A) Immunoblot analysis of PAICS knockdown cell lysates
using two independent shRNAs in DU145 cells. (B) The PAICS knockdown cells were utilized in the in vivo chicken chorioallantoic
membrane (CAM) assay. Tumor growth was measured in the knockdown as well as in control DU145 non-targeting shRNA cells. Tumor
size plotted corresponds to average tumor size of eight eggs per group. (C) and (D) PAICS knockdown reduces intravasation and
metastasis of DU145 cells in the CAM models. Metastasized cells to the lower CAM and liver of chicken embryos were quantified using
human Alu specific PCR. (E) PAICS knockdown in PC3 cells inhibits tumor growth in a mouse xenograft model. Athymic nude mice were
injected with PC3 cells that had either stable PAICS knockdown or non-targeting shRNA and tumors were monitored at indicated time
points and plotted. The solid black line is for Non-T shRNA, the dashed line is for shRNA1 and dotted line is for shRNA2. N¼ 8 mice per
group; P< 0.006, compared with non-targeting shRNA xenografts. Inset: Immunoblot analysis of PAICS using these stable knockdown
lysates. (F) Tumor weights of corresponding mouse xenograft models. Non-targeting shRNA was used as a control.
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various cancer models [34–37]. Earlier it was demon-
strated that BET inhibitor JQ1 reduces MYC expres-
sion in several cancers including multiple myeloma
[38], prostate [34], liver [39], bladder [40], pancreatic
ductal adenocarcinoma [37], and others. Moreover,
recent studies showed inducible MYC mediated tran-
scriptional activation of PAICS expression in andro-
gen-dependent prostate cancer cells [7,8]. To
therapeutically identify the role of JQ1 in MYC-
mediated PAICS expression, we treated androgen-
independent DU145, PC3, and androgen-sensitive
prostate cancer cell lines LnCaP and VCaP with 1 or
5mM of JQ1 for 48 hr. JQ1 treatment dramatically
reduced both MYC and PAICS expression both at
RNA (Supplementary Fig. S3) and protein (Fig. 4A)
levels. Next, we sought to conduct chromatin immu-
noprecipitation (ChIP) using MYC-specific antibody
and followed by qRTPCR using both DMSO and JQ1
treated ChIP-DNA. qRTPCR analysis using several
PAICS-promoter specific primers, we demonstrate
that JQ1 abolished MYC binding at the PAICS
promoter. Thus we conclude JQ1 can decrease PAICS
expression by directly interfering with MYC binding
to its promoter (Fig. 4B). Moreover, Barfeld et al.,
demonstrated that the purine biosynthetic pathway
genes-PAICS and IMPDH2 (IMP [Inosine 50-Mono-
phosphate] Dehydrogenase 2) are regulated by MYC
in prostate cancer [8].
DISCUSSION
Next-generation sequencing data have identified
molecular and genetic features that reveal prostate
cancer as a clinically heterogeneous disease [41].
Nearly 90% of prostate-specific antigen (PSA) screen-
ing identifies PCa to be localized at diagnosis [42].
Anti-androgen therapies that target the androgen
receptor remain important early and therapeutic
strategy that has improved survival. However, a
sizeable patient population develops resistant var-
iants that are aggressive and metastatic. Clinical
heterogeneity in this population leads to poor
Fig. 4. Bromodomain inhibitor JQ1 inhibits PAICS expression. Prostate cancer cells were treated with JQ1 for 48 hr. (A) Decreased
MYC and PAICS expression in prostate cancer cells treated with JQ1 (1 and 5mM) by immunoblot analysis. b-actin is used as a loading
control. (B) Chromatin immunoprecipitation analysis for the MYC occupancy on PAICS promoter in androgen sensitive prostate cancer
cell lines LnCaP and VCaP following JQ1 or DMSO treatment for 48 hr. Schematic representation of the PAICS genomic region showing
gene and amplicon positions. ChIP-qRTPCR analysis using various primers designed at indicated positions. ChIP was performed using
antibodies against MYC and a control IgG. Error bars: n¼ 3. All bar graphs are shown with SEM.
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prognosis and therefore dearth of therapeutic options.
Biomarkers that have clear diagnostic and predictive
value will lead to risk stratification and potential
systemic therapies. Recently, we demonstrated that
PAICS expression correlated with lung cancer pro-
gression [22]. In this study, we have identified PAICS
expression quantitatively correlate with different
stages of prostate cancer where it is negligible in
benign PCa, moderately expressed in localized PCa
and intensely expressed in metastatic PCa. Further,
we see concurrence of PAICS expression with respect
to transcript, protein, and immunohistochemistry in
patient samples. PAICS catalyzes the production of
Phosphoribosylaminoimidazolesuccinocarboxamide
(SAICAR), an intermediate metabolite in de novo
purine biosynthetic pathway [43,44].
Through several in vitro and in vivo studies we
demonstrate that PAICS is necessary for prostate
cancer proliferation and invasion. Specifically, we
show that PAICS function is imperative in DU145 and
PC3 both of which are androgen-independent pros-
tate cells. Thus we extrapolate that PAICS function is
necessary and therefore a possible therapeutic target
in androgen independent castration resistant prostate
cancer (CRPC) clinical settings. Furthermore, since de
novo purine biosynthetic pathway genes including
PAICS is expressed in transformed cells as compared
to salvage pathway in normal cells; therapeutic target-
ing of PAICS can avoid toxicity issues. Moreover,
SAICAR has potential value as non-invasive diagnos-
tic marker and chemical mimetic with therapeutic
implications.
Recent molecular analyses of 333 primary prostate
carcinomas identified 26% subset (of good and poor
clinical prognosis) with unexplained molecular alter-
ations that identified amongst others, amplifications
of chromosome eight spanning myc. MYCN was
identified to be amplified in prostate cancer with
lymph node metastasis [2]. MYCN was also identified
as oncogene in CRPC-neuroendocrine cancer [2].
Additionally, MYC amplification and over-expression
predicts poor outcome. MYC also has well-demon-
strated role in several anabolic pathways such as
amino acid metabolism and purine biosynthesis.
Previous work showed that inducible MYC over-
expression increased expression of de novo purine
biosynthesis pathway enzymes including PAICS, in
LnCaP (an androgen responsive PCa cell line) [7,8].
Though role of MYC as an oncogene remains indis-
putable, its role as transcription factor has made it
difficult to be therapeutically targeted. The “undrugg-
ability” of MYC has been circumvented by synthetic
lethal approaches [10] or targeting genes that are
either directly or indirectly regulated by MYC. In this
study, we identified JQ1, the bromodomain inhibitor
concurrently alleviates both MYC and PAICS expres-
sion across several PCa cells that are both androgen
sensitive and independent. We demonstrate that JQ1
mediates abrogation of PAICS expression by directly
reducing MYC occupancy on PAICS promoter. This
study advances previous observation of MYC medi-
ated de novo purine biosynthetic pathway regulation
by identifying JQ1 as potential therapeutic reagent for
MYC regulated gene, PAICS in prostate cancer cells.
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